Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial.
Scheck MK, Goetze TO, Ettrich TJ, Schmalenberg H, Clemens M, Mahlberg R, Heeg S, Kanzler S, Hapke G, Thuss-Patience P, Kestler A, Treschl A, Heidel S, Schiemer M, Sookthai D, Junge S, Pauligk C, Al-Batran SE, Lorenzen S. Scheck MK, et al. Among authors: thuss patience p. Oncol Res Treat. 2024;47(11):549-560. doi: 10.1159/000541174. Epub 2024 Sep 9. Oncol Res Treat. 2024. PMID: 39250905 Clinical Trial.
S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus.
Porschen R, Fischbach W, Gockel I, Hollerbach S, Hölscher A, Jansen PL, Miehlke S, Pech O, Stahl M, Vanhoefer U, Ebert MPA; und die Mitarbeiter der Leitlinienkommission; Collaborators:. Porschen R, et al. Z Gastroenterol. 2023 Jun;61(6):e209-e307. doi: 10.1055/a-1771-6953. Epub 2023 Jun 7. Z Gastroenterol. 2023. PMID: 37285869 Free article. German. No abstract available.
S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus.
Porschen R, Fischbach W, Gockel I, Hollerbach S, Hölscher A, Jansen PL, Miehlke S, Pech O, Stahl M, Vanhoefer U, Ebert MPA; und die Mitarbeiter der Leitlinienkommission; Collaborators:. Porschen R, et al. Z Gastroenterol. 2023 Jun;61(6):701-745. doi: 10.1055/a-1771-7087. Epub 2023 Jun 7. Z Gastroenterol. 2023. PMID: 37285870 Free article. German. No abstract available.
Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study.
Lordick F, Mauer ME, Stocker G, Cella CA, Ben-Aharon I, Piessen G, Wyrwicz L, Al-Haidari G, Fleitas-Kanonnikoff T, Boige V, Lordick Obermannová R, Martens UM, Gomez-Martin C, Thuss-Patience P, Arrazubi V, Avallone A, Shiu KK, Artru P, Brenner B, Buges Sanchez C, Chau I, Lorenzen S, Daum S, Sinn M, Merelli B, van Grieken NCT, Nilsson M, Collienne M, Giraut A, Smyth E. Lordick F, et al. Among authors: thuss patience p. Ann Oncol. 2024 Nov 13:S0923-7534(24)04906-8. doi: 10.1016/j.annonc.2024.10.829. Online ahead of print. Ann Oncol. 2024. PMID: 39542422 Free article.
Inflammatory stress determines the need for chemotherapy in patients with HER2-positive esophagogastric adenocarcinoma receiving targeted and immunotherapy.
Tintelnot J, Paschold L, Goekkurt E, Schultheiss C, Matschl U, Santos Cruz M, Bauer M, Wickenhauser C, Thuss-Patience P, Lorenzen S, Ettrich TJ, Riera-Knorrenschild J, Jacobasch L, Kretzschmar A, Kubicka S, Al-Batran SE, Reinacher-Schick A, Pink D, Bokemeyer C, Sinn M, Lindig U, Hinke A, Hegewisch-Becker S, Stein A, Binder M. Tintelnot J, et al. Among authors: thuss patience p. Cancer Immunol Res. 2024 Nov 11. doi: 10.1158/2326-6066.CIR-24-0561. Online ahead of print. Cancer Immunol Res. 2024. PMID: 39527097
Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study.
Li M, Meindl-Beinker NM, Maenz M, Betge J, Schulte N, Zhan T, Hofheinz RD, Vogel A, Angermeier S, Bolling C, de Wit M, Jakobs R, Karthaus M, Stocker G, Thuss-Patience P, Leidig T, Bauer H, Ebert MP, Haertel N. Li M, et al. Among authors: thuss patience p. J Geriatr Oncol. 2024 Sep;15(7):101838. doi: 10.1016/j.jgo.2024.101838. Epub 2024 Aug 3. J Geriatr Oncol. 2024. PMID: 39097500 Free article. Clinical Trial.
Effective symptom relief through continuous integration of palliative care in advanced renal cell carcinoma patients: comprehensive measurement using the palliative care base assessment.
Dörr A, Vogel I, Wittenbecher F, Westermann J, Thuss-Patience P, Ahn J, Pelzer U, Hardt J, Bullinger L, Flörcken A. Dörr A, et al. Among authors: thuss patience p. Palliat Care Soc Pract. 2024 Jun 24;18:26323524241260424. doi: 10.1177/26323524241260424. eCollection 2024. Palliat Care Soc Pract. 2024. PMID: 39045295 Free PMC article.
Reply to F. Salani et al.
Rau B, Thuss-Patience PC. Rau B, et al. Among authors: thuss patience pc. J Clin Oncol. 2024 May 20;42(15):1862-1863. doi: 10.1200/JCO.23.02784. Epub 2024 Mar 14. J Clin Oncol. 2024. PMID: 38484264 No abstract available.
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Masetti M, Al-Batran SE, Goetze TO, Thuss-Patience P, Knorrenschild JR, Goekkurt E, Folprecht G, Ettrich TJ, Lindig U, Luley KB, Pink D, Dechow T, Sookthai D, Junge S, Loose M, Pauligk C, Lorenzen S. Masetti M, et al. Among authors: thuss patience p. Int J Cancer. 2024 Jun 15;154(12):2142-2150. doi: 10.1002/ijc.34894. Epub 2024 Mar 6. Int J Cancer. 2024. PMID: 38447003 Clinical Trial.
131 results